Suchergebnisse - "Gaglione, Erika M"

PubPharm (11)

1

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Alsadhan, A. | Chen, J. | Gaglione, E. | +14

CommentIn: Clin Cancer Res. 2023 Sep 15;29(18):3560-3562. - PMID 37439706

2

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

enthalten in: Blood advances | 2023

von Mhibik, M. | Gaglione, E. | Eik, D. | +13

3

Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia

enthalten in: Journal for immunotherapy of cancer | 2022

von Cyr, M. | Mhibik, M. | Qi, J. | +11

4

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

enthalten in: Blood | 2021

von Mhibik, M. | Gaglione, E. | Eik, D. | +9

5

Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

enthalten in: Blood cancer discovery | 2021

von Shaffer, A. | Phelan, J. | Wang, J. | +28

CommentIn: Blood Cancer Discov. 2021 Nov;2(6):555-558. - PMID 35015676

6

Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia : a phase 2 study

enthalten in: Leukemia & lymphoma | 2021

von Desai, S. | Mo, C. | Gaglione, E. | +22

7

Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Baptista, M. | Baskar, S. | Gaglione, E. | +4

CommentIn: Clin Cancer Res. 2021 Aug 15;27(16):4465-4467. - PMID 34108178

8

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib : Development and Validation of a Four-Factor Prognostic Model

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Ahn, I. | Tian, X. | Ipe, D. | +10

CommentIn: J Clin Oncol. 2021 Feb 20;39(6):551-553. - PMID 33048620

9

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

enthalten in: Blood | 2021

von Pleyer, C. | Ali, M. | Cohen, J. | +11

CommentIn: Blood. 2021 Jan 14;137(2):144-146. - PMID 33443562

10

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

enthalten in: Blood | 2020

von Sun, C. | Nierman, P. | Kendall, E. | +18

CommentIn: Blood. 2020 Jul 2;136(1):4-6. - PMID 32614961